Although combinatory therapy with STAT3 inhibitors represents only an initial step towards progress in the management of EGFR mutant lung cancer, compelling evidence indicates the need for a switch from monotherapy to combination therapy and illustrates how pre-clinical research could pave the way to implement such clinical trials. Here, STAT3 is linked to lung carcinoma.